Navigation Links
Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium
Date:12/5/2008

tem, Ann Arbor Location: Exhibit Hall B -- Saturday, December 13, 2008, 10 a.m. - 10:15 a.m. Abstract #53 Oral presentation (General Session 5): "Risk of distant recurrence using Oncotype DX in postmenopausal primary breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study" Presenter: Mitch Dowsett, Ph.D., Royal Marsden Hospital, London Location: Exhibit Hall D

About Oncotype DX(R)

Oncotype DX is the first and only multi-gene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. Additionally, the test report provides quantitative scores for certain individual genes. Oncotype DX has been extensively evaluated in eleven clinical studies involving more than 4,000 breast cancer patients, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology. To date, 7,500 physicians have ordered more than 75,000 tests, and both Medicare and private health plans covering approximately 90 percent of U.S. insured lives provide reimbursement for Oncotype DX through contracts, agreements or policy decisions. Both the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network recommend the use of Oncotype DX for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive. For more information about Oncotype DX, please visit http://www.oncotypedx.com.

About Genomic Health

Genomic Health, Inc. (Nasdaq: GHDX) is a life science company focused on t
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS
2. Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products Neurodegenerative Diagnostics
3. Rosetta Genomics Announces Conference Call and Webcast of Third Quarter Financial Results
4. Transgenomic Awarded SBIR Grant to Support Development of SURVEYOR(R) Endonuclease Adaptor-ligated Libraries (SEAL) for Determining Whole Genome Sequence Variation
5. Genomic Health to Present at Stephens Fall Investment Conference
6. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
7. NeoGenomics to Present at the Rodman & Renshaw Healthcare Conference on November 10
8. Transgenomic to Present at Rodman & Renshaw 10th Annual Healthcare Conference
9. /C O R R E C T I O N -- Rosetta Genomics Ltd/
10. Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress
11. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) Centennial Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Array BioPharma Inc. (NASDAQ: ... reached a definitive agreement with Novartis Pharma AG to ... currently in Phase 3 development.  This agreement is conditional on ... PLC (GSK) on April 22, 2014, which are expected to ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Eckert & ... Mass Spectrometry (AMS) services to the pharmaceutical and biotech ... joined the company in the position of Director of ... of broad and valuable experience in drug metabolism and ...
(Date:1/22/2015)... 22, 2015  Transwestern | RBJ today announces the firm brokered ... for Shire a leading biopharmaceutical company, at Two Ledgemont Center ... Robert Richards , president, and Brian Cohen , ... entire five-floor building at 95 Hayden Ave. Photo ...
(Date:1/22/2015)... | RBJ today announces the firm brokered a long-term lease ... leading biopharmaceutical company, at Two Ledgemont Center in ... , president, and Brian Cohen , senior vice president, ... at 95 Hayden Ave. Photo - http://photos.prnewswire.com/prnh/20150122/170765 ...
Breaking Biology Technology:Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 2Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 3Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 4Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 5Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 6Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 7Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 2Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 3Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2
... PRINCETON, N.J., Dec. 8 BioWa, Inc., announced today ... its POTELLIGENT(R) Technology for,use in developing and commercializing select ... "GSK is recognized ... drug,discovery," said Dr. Masamichi Koike, BioWa President and CEO. ...
... Dec. 7 Data on Cytopia,s (ASX: CYT) JAK2 inhibitor CYT387 will ... Francisco. The talk will be presented by Dr Thomas Bumm ... CYT387 in an in- vivo model of myeloproliferative disorders. , ... Effects of CYT387, a Potent Novel JAK2 Inhibitor on ...
... Dynamic Alert,Limited (OTC Bulletin Board: DYMC) is pleased ... markets for its pharmaceutical product line-up. The,modalities will ... rapid onset,through oromucosal absorption, topical applications, such as ... Some products will have,specific uses, while others may ...
Cached Biology Technology:BioWa Licenses POTELLIGENT(R) Technology to GlaxoSmithKline for Use in Antibody Development and Commercialization 2Dynamic Outlines Initial Target Markets for Pharmaceutical Cannabinoid Products 2Dynamic Outlines Initial Target Markets for Pharmaceutical Cannabinoid Products 3
(Date:1/22/2015)... Washington , January 20, 2015 Investorideas.com, ... tech stocks, releases video from the CES 2015 (Consumer Electronics ... Apollo Robbins . Apollo shows how easily ... smart wallet, a product of NXT-ID, Inc. (NASDAQ: ...
(Date:1/22/2015)... MUNICH , January 22, 2015 ... its tenth year  The European Patent Office to present ... Two British nominations to be featured: Christofer Toumazou ... week featuring former finalists and winners of the Award   ...
(Date:1/22/2015)... EyeLock, Inc. , a market leader of iris-based identity authentication ... to the new role of Senior Vice President of Mobile ... mobile platforms and wearable solutions for EyeLock,s technologies. Gerber brings ... semiconductor industry to his role at EyeLock, with expertise in ...
Breaking Biology News(10 mins):Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2
... Institute have identified a molecular interaction that triggers a ... attacking this target with selective drugs might improve treatment. ... a team led by Qunyan Yu, MD, and Peter ... of a certain mutated oncogene and the newly described ...
... all-important channels that control the flow of information in and ... for the split to come when a cell divides. Now, ... Biological Studies watched as new funnel-like pore structures formed from ... This discovery adds to the picture of how a cell ...
... a gene previously linked to impulsive violence appears ... memory and thinking in humans, researchers at the ... Mental Health (NIMH) have found. Brain scans revealed ... to have relatively smaller emotion-related brain structures, a ...
Cached Biology News:New cellular flaw found in some virulent breast cancers 2New cellular flaw found in some virulent breast cancers 3Researchers solve mystery of how nuclear pores duplicate before cell division 2Aggression-related gene weakens brain's impulse control circuits 2Aggression-related gene weakens brain's impulse control circuits 3
... of Japan, also named Sendai virus) Envelope ... of molecules by means of membrane fusion. ... Protein, Oligo, cDNA, Antibodies, Vector, and Biomolecule ... EX has a high fusing capability in ...
... S. pombe Whole Genome ChIP-on-chip Microarray ... of yeast (S. pombe) DNA binding ... with Agilent DNA microarrays. This set ... data with greater true binding events ...
... designed for easy transformation of the budding ... successful transformation simply by mixing a plasmid ... yeast cells. No complicated steps, such as ... kit is particularly well suited for high-throughput ...
... The STag Purification Kits enable rapid analytical ... fusion proteins produced from appropriate vectors. Sufficient ... to 1 mg target protein under native ... with S-protein Agarose, which specifically retains STag ...
Biology Products: